Back

Incidence, medical therapy, and outcomes in heart failure with improved ejection fraction across guideline definitions

11 May 2026 (09:12 - 09:21)
Organised by: Logo
Congress Presentation Part of: The changing landscape of heart failure Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Arash Agharahmanian

Kaiser Permanente, San Francisco Medical Centre and Medical Offices, San Francisco (United States of America)

6 More presentations in this session

Presentation thumbnail
Viral respiratory tract infections in heart failure with mildly reduced and preserved ejection fraction: a secondary analysis of the FINEARTS-HF trial
Doctor R. Helseth (Boston, US)
Abstract Slides Video
Presentation thumbnail
Integrating body mass index and waist-to-hip ratio identifies the 'lemon-on-sticks' phenotype as a high-risk subgroup in heart failure
Miss C. van der Hoef (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Clustering patterns of evidence-based therapy identifies distinct phenotypes in heart failure with reduced ejection fraction: a machine learning analysis of the Swedish heart failure registry
Assistant Professor A. Uijl (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Evolving trends in treatments, morbidity, and mortality in heart failure: 30 years of data from the italian network of heart failure (IN-HF) registry
Professor A. Maggioni (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Trends in heart failure etiologies and comorbidities: a nationwide analysis of 700,000 individuals over two decades
Doctor D. Lindholm (Norrtalje, SE)
Abstract Slides Video

Access the full session

Session thumbnail
The changing landscape of heart failure
Video

The Event

Event poster

Heart Failure 2026

11 May 2026 09:12 CET
You may be interested in
thumbnail
Congress Session
Heart failure (HF) with improved ejection fraction: how to approach a patient with HF remission
thumbnail
Congress Presentation
How to approach a patient with HFimpEF
thumbnail
Congress Presentation
Clinical outcomes and latent risk in HFimpEF: insights from real-world data

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources